Healthcare
Kaken Pharmaceutical Co., Ltd.(KKPCF)
Live Price
Offline$26.00
+0.00% today
1Y Change
-7.44%
Window
Jun 26, 2025 → Jun 24, 2026
- Market Cap
- $154.31B
- Revenue Growth
- +30.5%
- EPS Growth
- +71.8%
- Dividend Yield
- 4.7%
Coverage: 250 bars · Jun 26, 2025 → Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Kaken Pharmaceutical Co., Ltd. (KKPCF) is a Healthcare stock with a market cap of $154.31B and listed on OTC. The stock last traded around $26.00 and down 7.4% across the available one-year price window (Jun 26, 2025 → Jun 24, 2026). Baseline metrics include revenue growth of +30.5%, EPS growth of +71.8%, a dividend yield of 4.7%. What stands out right now is revenue +30.5%, EPS +71.8%, free cash flow +6092.2% with operating margin -5.4% and ROIC -2.2%. The dividend matters to the case here, with a current yield around 4.7%. Valuation is more restrained than many high-expectation growth names at price/sales 2.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines KKPCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+30.5% vs +7.6% peer median
Operating Margin
Below sector median
-5.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +30.5% and EPS at +71.8%, with operating margin around -5.4%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 4.7%, which matters if the thesis depends on income as much as growth.
Benchmark Edge
KKPCF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
KKPCF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
KKPCF Max Drawdown
-15.81%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for KKPCF and SPY.
Company Overview
Kaken Pharmaceutical Co., Ltd.
Other OTC
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
- Leadership
- Hiroyuki Horiuchi
- IPO Date
- Dec 9, 2020
- Employees
- 1.1k
- Street Address
- 28-8, Honkomagome 2-chome
- Mailing
- Tokyo, 113-8650
- Region
- Tokyo, JP
- Reporting Currency
- USD
- Investor Line
- 81 3 5977 5001
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- 2.0
- Price/Book
- 1.1
Growth
- Revenue
- +30.5%
- EPS
- +71.8%
- Free Cash Flow
- +6092.2%
Profitability
- Gross Margin
- 52.7%
- Operating Margin
- -5.4%
- Net Margin
- -5.1%
- ROE
- -2.6%
- ROIC
- -2.2%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 4.09
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.